Ionis Pharmaceuticals Inc.

06/10/2025 | Press release | Distributed by Public on 06/10/2025 04:02

Proxy Results (Form 8-K)

Item 5.07
Submission of Matters to a Vote of Security Holders.
Ionis Pharmaceuticals, Inc. (the "Company") held its virtual Annual Meeting of Stockholders on June 5, 2025. The stockholders considered four proposals, each of which is described in more detail in the Company's definitive proxy statement dated April 25, 2025.
Proposal 1: Election of directors to hold office until the 2028 Annual Meeting:
FOR
AGAINST
ABSTAIN
BROKER NON-VOTES
Allene M. Diaz
134,533,610
3,812,549
64,043
10,701,820
Michael Hayden
133,250,556
5,107,295
52,351
10,701,820
Joseph Klein, III
127,135,692
11,224,182
50,328
10,701,820
Joseph Loscalzo
108,835,662
29,465,062
109,478
10,701,820

The Company's stockholders elected the foregoing candidates by affirmative votes by a majority of the votes cast in the election with respect to each nominee.
Proposal 2: An advisory vote on the compensation paid to the Company's executive officers, including the following resolution:

"RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed in this Proxy Statement for the 2025 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the Securities and Exchange Commission."
FOR
AGAINST
ABSTAIN
BROKER NON-VOTES
132,567,606
5,738,006
104,590
10,701,820

The Company's stockholders approved the foregoing proposal.
Proposal 3: Approval of an amendment of the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 4,000,000 shares to an aggregate of 42,500,000 shares:
FOR
AGAINST
ABSTAIN
BROKER NON-VOTES
108,160,711
30,105,665
143,826
10,701,820

The Company's stockholders approved the foregoing proposal.
Proposal 4: Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year:
FOR
AGAINST
ABSTAIN
BROKER NON-VOTES
144,587,537
4,426,728
97,757
0

The Company's stockholders approved the foregoing proposal.

Ionis Pharmaceuticals Inc. published this content on June 10, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 10, 2025 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io